Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG₁ and IgG₄ against the Major Birch Pollen Allergen Bet v 1.

ABSTRACT: Birch pollen allergy is among the most prevalent pollen allergies in Northern and Central Europe. This IgE-mediated disease can be treated with allergen immunotherapy (AIT), which typically gives rise to IgG antibodies inducing tolerance. Although the main mechanisms of allergen immunotherapy (AIT) are known, questions regarding possible Fc-mediated effects of IgG antibodies remain unanswered. This can mainly be attributed to the unavailability of appropriate tools, i.e., well-characterised recombinant antibodies (rAbs). We hereby aimed at providing human rAbs of several classes for mechanistic studies and as possible candidates for passive immunotherapy. We engineered IgE, IgG₁, and IgG₄ sharing the same variable region against the major birch pollen allergen Bet v 1

SUBMITTER: Kohler VK 

PROVIDER: S-EPMC7460837 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature